新西兰批准自2025年12月1日起五种新的治疗方法,包括第一种癌症药物Pheesgo,供私人使用。 New Zealand approves five new treatments, including first cancer drug Phesgo, for private use starting Dec. 1, 2025.

药店已批准为新西兰的五种新治疗方案提供资金,包括自2025年12月1日起在私立医院提供的首种癌症药物Pheesgo。 Pharmac has approved funding for five new treatments in New Zealand, including the first cancer medicine, Phesgo, available in private hospitals starting 1 December 2025. 创伤后精神紧张症和pertuzumab的亚皮层配方减少了治疗时间,减轻了病人在转诊护理环境中的压力,预计五年内将节省数千个医院注射小时和1 100万美元。 The subcutaneous formulation of trastuzumab and pertuzumab reduces treatment time, eases patient stress from switching care settings, and is expected to save thousands of hospital infusion hours and $11 million over five years. 药房还取消了仅由医院对Faricimab的限制,扩大了眼科治疗的机会。 Pharmac also removed hospital-only restrictions for faricimab, expanding access to eye treatments. 这些变化是继6.04亿美元的资金增加和支持政府实现更快、更容易获得的癌症护理和改善早期发现的目标之后发生的。 The changes follow a $604 million funding boost and support government goals for faster, more accessible cancer care and improved early detection.